News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
Conferences
| During the year, Debiopharm Group will be present at selected events, such as scientific roundtables, conferences, presentations etc.
| ||||||||||||
| ||||||||||||
| ||||||||||||